Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Blinktbi
AddedFeb 15, 2024
UpdatedJun 18, 2026
Blinktbi

Blinktbi

EyeStat: World's first FDA-cleared device for quick, objective blink reflex assessment.

HQ
Charleston, SC, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Blinktbi, founded with a vision to revolutionize medical diagnostics, focuses on developing innovative medical devices. Their flagship product, EyeStat, is the world's first FDA-cleared device designed for the rapid and objective assessment of the blink reflex. This technology aims to provide immediate and quantitative data, particularly useful for identifying abnormal blink patterns associated with traumatic brain injuries. Blinktbi targets healthcare providers and sports organizations, emphasizing the importance of quick and accurate diagnostics in medical and athletic settings.

Notable affiliations include collaborations with clinical experts and research institutions to validate and expand the applications of their technology. EyeStat's FDA clearance marks a significant achievement, underscoring its reliability and potential impact on medical diagnostics. By providing a swift and objective method to assess blink reflexes, Blinktbi has made a substantial contribution to the early detection and management of traumatic brain injuries, enhancing patient care and safety in high-risk environments like sports.

Blinktbi - Similar Companies

Oculogica logo

Oculogica

oculogica.com

Blink Technologies logo

Blink Technologies

NeuroChaos Solutions logo

NeuroChaos Solutions

Rebion logo

Rebion

Eyebot logo

Eyebot

eyebot.tech

Brainbox Solutions logo

Brainbox Solutions

brainboxinc.com

neuroFit logo

neuroFit

neurofit.tech

Epic Neuro logo

Epic Neuro

International Biomedical Devices logo

International Biomedical Devices

aperturectc.com

Banyan Biomarkers logo

Banyan Biomarkers

Globe Biomedical logo

Globe Biomedical

Lygent logo

Lygent

Bioxytech Retina logo

Bioxytech Retina

bioxytech.com

Sync Think logo

Sync Think

syncthink.com

BrainScope Company logo

BrainScope Company

Blinktbi - Quick Facts

Who are Blinktbi's competitors?

Companies similar to Blinktbi include Oculogica, Blink Technologies, NeuroChaos Solutions and Rebion.

When was Blinktbi founded?

Blinktbi was founded in 2017.

Where is Blinktbi's headquarters located?

Blinktbi's headquarters is located in Charleston, SC, US.

When was Blinktbi's last funding round?

Blinktbi's most recent funding round was for $6M (USD) in January 2020.

How much has Blinktbi raised to-date?

As of Jan 15, 2020, Blinktbi has raised a total of $7.6M (USD).

How many employees does Blinktbi have?

Blinktbi has 35 employees as of Feb 5, 2024.

Blinktbi - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Medical Devices
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified